Ticker

Annexon (NASDAQ: ANNX) President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual Needham Healthcare Conference, describing 2026 as a "win year" after more than a decade of work developing therapies that target the classical complement pathway. Key milestones highlighted for 2026 Love said the company expects multiple

Shares of Annexon, Inc. (NASDAQ: ANNX - Get Free Report) traded down 6.1% on Friday. The company traded as low as $5.82 and last traded at $5.7650. 799,310 shares traded hands during trading, a decline of 70% from the average session volume of 2,644,675 shares. The stock had previously closed at $6.14. Wall Street Analysts

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq.

The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA